Dinah W Y Sah

Summary

Affiliation: Alnylam Pharmaceuticals
Country: USA

Publications

  1. ncbi Therapeutic potential of RNA interference for neurological disorders
    Dinah W Y Sah
    Alnylam Pharmaceuticals Inc, Cambridge, MA 02142, USA
    Life Sci 79:1773-80. 2006
  2. pmc A status report on RNAi therapeutics
    Akshay K Vaishnaw
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, MA 02142, USA
    Silence 1:14. 2010
  3. pmc Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
    Akin Akinc
    Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA
    Mol Ther 18:1357-64. 2010
  4. ncbi Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes
    William Querbes
    Alnylam Pharmaceuticals, Inc, Cambridge, Massachusetts 02142, USA
    Oligonucleotides 19:23-29. 2009
  5. pmc Oligonucleotide therapeutic approaches for Huntington disease
    Dinah W Y Sah
    Alnylam Pharmaceuticals Inc, Cambridge, Massachusetts, USA
    J Clin Invest 121:500-7. 2011
  6. doi Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery
    Qingmin Chen
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, MA 02142, USA
    J Control Release 144:227-32. 2010
  7. pmc Lipid-like materials for low-dose, in vivo gene silencing
    Kevin T Love
    Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 107:1864-9. 2010
  8. doi Novel therapeutic modalities to address nondrugable protein interaction targets
    Errol B De Souza
    Archemix Corporation, Cambridge, MA 02142, USA
    Neuropsychopharmacology 34:142-58. 2009
  9. pmc A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
    Akin Akinc
    David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Nat Biotechnol 26:561-9. 2008
  10. ncbi RNAi therapeutics: a potential new class of pharmaceutical drugs
    David Bumcrot
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, MA 02142, USA
    Nat Chem Biol 2:711-9. 2006

Collaborators

  • Muthiah Manoharan
  • Kevin Fitzgerald
  • Akin Akinc
  • Kathryn A Whitehead
  • Daniel G Anderson
  • J├╝rgen Soutschek
  • Hans Peter Vornlocher
  • Marino Zerial
  • William Querbes
  • Pei Ge
  • Akshay K Vaishnaw
  • Kevin T Love
  • Qingmin Chen
  • Victor Kotelianski
  • Lubomir Nechev
  • Errol B De Souza
  • Jeffrey W Hewett
  • Victor Koteliansky
  • Chunhua Yang
  • David Bumcrot
  • Ka Ning Yip
  • William Cantley
  • Christopher G Levins
  • Jared Gollob
  • Kallanthottathil G Rajeev
  • John Maraganore
  • Maria Frank-Kamenetsky
  • Christina Gamba-Vitalo
  • Rachel Meyers
  • David Butler
  • June Qin
  • Tony de Fougerolles
  • J Robert Dorkin
  • Antonin de Fougerolles
  • Kerry P Mahon
  • Martin A Maier
  • Rene Alvarez
  • Renta Hutabarat
  • Rajendra K Pandey
  • Liu Liang Qin
  • Robert Langer
  • Timothy Racie
  • Ligang Zhang
  • Jason Costigan
  • Sharon T Cload
  • Martin Maier
  • Yupeng Fan
  • Wenjun Zhang
  • Klaus Charisse
  • Patrick Shannon Pendergrast
  • Brian Niland
  • Philipp Hadwiger
  • Xandra O Breakefield
  • Flavia C Nery
  • Bakhos A Tannous
  • Pamela Tan
  • David Hutto

Detail Information

Publications13

  1. ncbi Therapeutic potential of RNA interference for neurological disorders
    Dinah W Y Sah
    Alnylam Pharmaceuticals Inc, Cambridge, MA 02142, USA
    Life Sci 79:1773-80. 2006
    ....
  2. pmc A status report on RNAi therapeutics
    Akshay K Vaishnaw
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, MA 02142, USA
    Silence 1:14. 2010
    ....
  3. pmc Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
    Akin Akinc
    Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA
    Mol Ther 18:1357-64. 2010
    ..Both apoE-based endogenous and GalNAc-based exogenous targeting appear to be highly effective strategies for the delivery of iLNPs to liver...
  4. ncbi Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes
    William Querbes
    Alnylam Pharmaceuticals, Inc, Cambridge, Massachusetts 02142, USA
    Oligonucleotides 19:23-29. 2009
    ..Taken together, these results show for the first time robust RNAi within oligodendrocytes in vivo and demonstrate the important potential of siRNAs in the treatment of CNS disorders involving oligodendrocyte pathology...
  5. pmc Oligonucleotide therapeutic approaches for Huntington disease
    Dinah W Y Sah
    Alnylam Pharmaceuticals Inc, Cambridge, Massachusetts, USA
    J Clin Invest 121:500-7. 2011
    ..Delivery remains a key challenge for translational success, especially with chronic therapy. The potential of disease-modifying oligonucleotide approaches for Huntington disease will be revealed as they progress into clinical trials...
  6. doi Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery
    Qingmin Chen
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, MA 02142, USA
    J Control Release 144:227-32. 2010
    ....
  7. pmc Lipid-like materials for low-dose, in vivo gene silencing
    Kevin T Love
    Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 107:1864-9. 2010
    ..03 mg/kg. To our knowledge, this formulation facilitates gene silencing at orders-of-magnitude lower doses than required by any previously described siRNA liver delivery system...
  8. doi Novel therapeutic modalities to address nondrugable protein interaction targets
    Errol B De Souza
    Archemix Corporation, Cambridge, MA 02142, USA
    Neuropsychopharmacology 34:142-58. 2009
    ..Finally, examples of their application as therapeutics for the treatment of pain and some neurological disorders such as Alzheimer's disease, multiple sclerosis, Huntington's disease, and Parkinson's disease are provided...
  9. pmc A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
    Akin Akinc
    David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Nat Biotechnol 26:561-9. 2008
    ..The studies reported here suggest that these materials may have broad utility for both local and systemic delivery of RNA therapeutics...
  10. ncbi RNAi therapeutics: a potential new class of pharmaceutical drugs
    David Bumcrot
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, MA 02142, USA
    Nat Chem Biol 2:711-9. 2006
    ..With advances in this area and the commencement of multiple clinical trials with RNAi therapeutic candidates, a transformation in modern medicine may soon be realized...
  11. ncbi Distribution of GDNF family receptor alpha3 and RET in rat and human non-neural tissues
    Chunhua Yang
    BiogenIdec, Inc, 14 Cambridge Center, Cambridge, MA 02142, USA
    J Mol Histol 37:69-77. 2006
    ..In other tissues, sub-populations of cells expressed either GFRalpha3- or RET-like immunoreactivity. The functional consequences of GFRalpha3 expression in non-neural cells remain to be determined...
  12. ncbi New approaches for the treatment of pain: the GDNF family of neurotrophic growth factors
    Dinah W Y Sah
    Alnylam Pharmaceuticals, Inc, 300 Third Street, Cambridge, MA 02142, USA
    Curr Top Med Chem 5:577-83. 2005
    ..Structural considerations, particularly with regard to implications for binding interactions and biological activity are discussed...
  13. pmc siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells
    Jeffrey W Hewett
    Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Hum Mol Genet 17:1436-45. 2008
    ..The ability of allele-specific siRNA for torsinADeltaE to normalize secretory function in DYT1 patient cells supports its potential role as a therapeutic agent in early onset torsion dystonia...